We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ALA market cap is 183.78M. The company's latest EPS is AUD -0.0083 and P/E is -20.48.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 676k | 1.16M | 296k | 1.45M | 1.95M |
| Operating Income | -10.61M | -4.81M | -8.43M | -10.19M | -8.88M |
| Net Income | -9.94M | -5.05M | -8.62M | -10.18M | -8.75M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 6.71M | 10.69M | 9.21M | 5.47M | 13.29M |
| Total Liabilities | 2.57M | 1.71M | 1.6M | 1.69M | 2.06M |
| Total Equity | 4.14M | 8.98M | 7.62M | 3.78M | 11.23M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -2.88M | -3.55M | -6.27M | -6.4M | -6.91M |
| Investing | -388k | -514k | -566k | 95k | -179k |
| Financing | -64k | 9.8M | 6.19M | 5.41M | 14.61M |
| Market Cap | 183.78M |
| Price to Earnings Ratio | -20.48 |
| Price to Sales Ratio | 89.47 |
| Price to Cash Ratio | 14.05 |
| Price to Book Ratio | 15.9 |
| Dividend Yield | - |
| Shares Outstanding | 1.05B |
| Average Volume (1 week) | 152.9k |
| Average Volume (1 Month) | 854.67k |
| 52 Week Change | 45.83% |
| 52 Week High | 0.21 |
| 52 Week Low | 0.105 |
| Spread (Intraday) | 0.01 (2.86%) |
| Company Name | Arovella Therapeutics Ltd |
| Address |
level 3 melbourne, victoria 3053 |
| Website | https://www.sudapharma.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
